CIDEB and hepatocellular carcinoma: Loss-of-function variants in CIDEB were associated with a reduced risk of liver disease of any cause (OR, 0.67; 95% CI, 0.57–0.79) and lower risk of HCC (OR, 0.51; 95% CI, 0.26–1) in an exome-wide association analysis that compared participants with various types of liver diseases with controls without liver disease, analyzing multiple biobanks in Europe, United States, and UK.117